Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.
BMJ Case Rep
; 14(1)2021 Jan 28.
Article
in English
| MEDLINE | ID: covidwho-1054634
ABSTRACT
Convalescent plasma, which contains antibodies from recovered individuals, has been used as an effective treatment for infectious diseases in the past and is currently being used as a potential treatment option for COVID-19. Multiple studies have reported this treatment to be safe. We report a case of a patient who developed acute respiratory distress syndrome (ARDS) with features suggestive of transfusion-related acute lung injury after being treated with convalescent plasma for COVID-19. We emphasise the need to be aware of the potential risk of transfusion reactions and disease worsening with convalescent plasma administration and to weigh the risk and benefits of this therapy before administration to patients and propose that further study be done regarding the potential risks of convalescent plasma.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Transfusion-Related Acute Lung Injury
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2020-239762
Similar
MEDLINE
...
LILACS
LIS